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Abstract: The development of personalized medicine with a focus
on novel targeted therapies has supplanted the one-size-fits-all
approach to the treatment of many cancers, including non-small cell
lung cancer. Targeted therapies, if given to a patient subpopulation
enriched by the presence of relevant molecular targets, can often
abrogate cell signaling that perpetuates cancer progression. Crit-
ical targets activating procancer pathways include, but are not
limited to, epidermal growth factor receptor (EGFR), hepatocyte
growth factor receptor (MET), vascular endothelial growth factor
(VEGF), VEGF receptor, GTPase KRAS (KRAS), receptor ty-
rosine protein kinase erbB-2 (HER2), echinoderm microtubule-
associated protein-like 4-anaplastic lymphoma kinase (EML4-
ALK), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha isoform (PIK3CA), serine/threonine-protein kinase
B-raf (BRAF), and insulin-like growth factor 1 receptor (IGF-
1R). Some target-directed therapies, such as epidermal growth
factor receptor tyrosine kinase inhibitors and anti-VEGF mono-
clonal antibody, have already been approved for clinical use.
Others, such as those targeted to MET, VEGFR, HER2, PIK3CA,
and IGF-1R, are in clinical testing. This review describes molecular
targets in non-small cell lung cancer that are in development or being
clinically applied and their implications for developing novel anticancer
therapies for this previously refractory malignancy.
Key Words: Non-small cell lung cancer, Molecular target, Muta-
tion, EGFR, VEGF, VEGFR, KRAS, BRAF, PIK3CA, EML4-ALK,
IGF-1R.
(J Thorac Oncol. 2011;6: 1601–1612)
Major discoveries in the molecular biology of humanmalignancies have led to successful application of
targeted therapeutic strategies in several cancers.1–5 Substan-
tial progress has been made toward understanding the tumor
biology of non-small cell lung cancer (NSCLC) during the
last few years. Epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) (erlotinib) and antibody
targeting vascular endothelial growth factor (VEGF) (bevaci-
zumab) have been approved for clinical use.6,7 In addition,
other therapies targeting EGFR, hepatocyte growth factor
receptor (MET), VEGF receptor (VEGFR), echinoderm mi-
crotubule-associated protein-like 4-anaplastic lymphoma ki-
nase (EML4-ALK), receptor tyrosine protein kinase erbB-2
(HER2), phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha isoform (PIK3CA), serine/threo-
nine protein kinase B-raf (BRAF), insulin-like growth
factor 1 receptor (IGF-1R), and others, are in clinical
testing.8–10 Furthermore, the first results of large-scale
efforts investigating relevant molecular aberrations have
been recently published.11,12 This article delineates the role
of molecular targets in NSCLC that are in development or
being clinically applied.
EGFR
EGFR is instrumental in activating the phosphoinosi-
tide 3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) and RAS/RAF/MEK signaling pathways in solid
tumors (Figure 1).13 These pathways are important in tumor
cell growth, local invasion, angiogenesis, protein translation,
autophagy, and cell metabolism. EGFR gene amplification/
increased copy number is present in 30 to 60%14–16 of
NSCLC cases. Furthermore EGFR mutations in the tyrosine
kinase domain are found in approximately 10% of white
patients and in more than 30% of East Asian patients with
NSCLC (Table 1).17–20 EGFR has been clinically investigated
for more than a decade as a potential target for anticancer
therapy. Therapeutic strategies for targeting EGFR include
TKIs and monoclonal antibodies.
EGFR TKIs as Single Agents
EGFR TKI erlotinib gained Food and Drug Adminis-
tration and European Medicines Agency (EMEA) approval
based on the results of a pivotal international phase III trial
(BR.21), which demonstrated a survival advantage compared
with placebo (6.7 versus 4.7 months, hazard ratio [HR]: 0.70,
p  0.001) in 731 previously treated patients with advanced
NSCLC (Table 2).6 In a retrospective subanalysis, patients
who had tumors with EGFR-activating mutations had a HR
for death of 0.65, but this was not statistically significant
which may have been attributable to the small number of
patients assessed. A trial Iressa Survival Evaluation in Lung
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Cancer (ISEL) testing gefitinib versus placebo in 1692 pre-
viously treated patients with advanced NSCLC showed no
survival advantage (Table 2).43 Median survival trended to-
ward favoring gefitinib (5.6 versus 5.1 months, p  0.087),
and time to treatment failure was longer in the gefitinib group
than in the placebo group (3.0 versus 2.6 months, p 
0.0006). EGFR mutations were detected in 12% of tested
samples and were associated with better response to gefitinib
compared with patients with wild-type EGFR (37.5% versus
2.6%). Unfortunately, the responding subgroup was too small
to be evaluated for survival.
The hypothesis that EGFR TKIs are active in patients
harboring EGFR mutations was tested in multiple phase II
trials.18,21,69–71 The largest trial carried out by The Spanish
Lung Cancer Group screened 2105 chemonaïve or previously
treated patients with NSCLC and found EGFR mutations in
350 patients (16.6%). Of these 350 patients, 217 were treated
with erlotinib, yielding an overall response rate (RR) of
70.6%, median progression-free survival (PFS) of 14 months,
and median overall survival (OS) of 27 months.18 In the
first-line setting, Mok et al.48 carried out a phase III random-
ized trial Iressa Pan-Asia Study (IPASS) comparing gefitinib
with standard carboplatin/paclitaxel chemotherapy in 1217
chemonaïve East Asian patients with advanced lung adeno-
carcinoma who had a limited history of smoking (never
smokers and ex light smokers) (Table 2). The trial exceeded
its primary end point (noninferiority), showing in the intent-
to-treat population a 26% risk reduction of disease progres-
sion with gefitinib (HR: 0.74, p  0.001). Gefitinib also
achieved a greater RR compared with carboplatin/paclitaxel
FIGURE 1. Therapeutic targets
and cancer.
TABLE 1. Molecular Abnormalities in NSCLC
Molecular Abnormality
Frequency in
NSCLC (%) Clinical Implications
EGFR mutation 10a–30b17–20 Sensitivity to EGFR TKIs
EGFR increased copy number 30–6014–16 Conflicting data on sensitivity to EGFR TKIs and monoclonal antibodies
MET amplification 5–2021–25 Resistance to EGFR TKIs, indicates worse prognosis
MET mutation 326–28 May be involved in EGFR resistance
EML4-ALK fusion 5–729,30 Sensitivity to ALK inhibitors
KRAS mutation 10–3016,31–34 Associated with smoking, indicates worse prognosis
HER2 mutation 3–1035,36 Resistance to EGFR TKIs
PIK3CA amplification 1237,38 May be involved in EGFR TKIs resistance
PIK3CA mutation 2–1338–40 May be involved in EGFR TKIs resistance and may predict response to
PI3K/AKT/mTOR inhibitors
BRAF mutation 341 Associated with smoking
IGF-1R increased copy number 2742 Indicates better prognosis in operable NSCLC
a Frequency in Caucasian population.
b Frequency in East Asian population.
NSCLC, non-small cell lung cancer; TKIs, tyrosine kinase inhibitors.
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TABLE 2. Major Randomized Trials with Targeted Therapies for Advanced Non-small Cell Lung Cancer (Outcomes Which are
Statistically Significant are Depicted in Bold on Green Background)
Study Phase, Setting
Enrichment for










Shepherd et al.6 III, 2nd line and 3rd line No Erlotinib 488 8.7 2.2 6.7
Placebo 243 0.7 1.8 4.7
Thatcher et al.43 III, 2nd line and 3rd line No Gefitinib 1129 8 3a 5.6
Placebo 563 1.3 2.6a 5.1
Giaccone et al.44 III, 1st line No CG  gefitinib (500 mg) 365 50.3 5.5 9.9
CG  gefitinib (250 mg) 365 51.2 5.8 9.9
CG  placebo 363 47.2 6 10.9
Herbst et al.45 III, 1st line No CbP  gefitinib (500 mg) 347 30 4.6 8.7
CbP  gefitinib (250 mg) 345 30.4 5.3 9.8
CbP  placebo 345 28.7 5.5 9.9
Gatzemeier et al.46 III, 1st line No CG  erlotinib 580 31.5 5.5 10
CG  placebo 579 29.9 5.7 10.3
Herbst et al.47 III, 1st line No CbP  erlotinib 539 21.5 5.1 10.6
CbP  placebo 540 19.3 4.9 10.5
Mok et al.48 III, 1st line Asians,
adenocarcinoma,
never smokers
Gefitinib 609 43 5.7b 18.6
CbP 608 32.2 5.8 17.3
Maemondo et al.49 III, 1st line EGFR mutations Gefitinib 115 73.7 10.8 30.5
CbP 115 30.7 5.4 23.6
Mitsudomi et al.50 III, 1st line EGFR mutations Gefitinib 88 62.1 9.2 NR
CD 89 32 6.3 NR
Zhou et al.51 III, 1st line EGFR mutations Erlotinib 83 83 13.1 NR
CbG 82 36 4.6 NR
Cappuzzo et al.52 III, maintenance after 1st
line
No Erlotinib 438 11.9 2.9 12
Placebo 451 5.4 2.6 11.1
Miller et al.53 III, maintenance after 1st
line
No Erlotinib  bevacizumab 370 NR 4.8 14.4
Placebo  bevacizumab 373 NR 3.7 13.3
Miller et al.54 III, 2nd line and 3rd line, prior
EGFR TKIs12 wk
No Afatinib 390 7.4 3.3 10.8
Placebo 195 0.5 1.1 12
Boyer et al.55 III, 2nd line and 3rd line, no
prior EGFR TKIs
No PF00299804 94 17.1 2.9 NR
Placebo 94 4.3 1.9 NR
Pirker et al.56 III, 1st line EGFR IHC CV  cetuximab 557 36 4.8 11.3
CV 568 29 4.8 10.1
Lynch et al.57 III, 1st line No Cb  taxane  cetuximab 338 25.7 4.4 9.69
Cb  taxane 338 17.2 4.24 8.38
VEGF and VEGFR
studies
Sandler et al.7 Phase III, 1st line No CbP  bevacizumab 434 35 6.2 12.3
CbP 444 15 4.5 10.3
Reck et al.58,59 Phase III, 1st line No CG  bevacizumab (7.5 mg/kg) 345 34.1 6.8 13.6
CG  bevacizumab (15 mg/kg) 351 30.4 6.6 13.4
CG  placebo 347 20.1 6.2 13.1
Scagliotti et al.60 Phase III, 1st line No CbP  sorafenib 464 27.4 4.6 10.7
CbP  placebo 462 24 5.4 10.6
Schiller et al.61 Phase II, 3rd line No Sorafenib 51 3 3.6 11.9
Placebo 32 2 2.0 9.0
Herbst et al.62 Phase III, 2nd line No Vandetanib  docetaxel 694 17 4 10.6
Placebo  docetaxel 697 10 3.2 10
de Boer et al.63 Phase III, 2nd line No Vandetanib  pemetrexed 256 19 4.1 10.5
Placebo  pemetrexed 278 8 2.8 9.2
Natale et al.64 Phase III, 2nd line and 3rd
line
No Vandetanib 623 12 2.6 6.9
Erlotinib 617 12 2 7.8
(Continued)
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(43% versus 32.2%, p 0.001). OS was comparable between
the two arms, but the patients on gefitinib had a better quality
of life as assessed using the FACT-L questionnaire. Tissue
samples for planned posthoc analysis were available for 683
(56.1%) patients, and EGFR mutation analysis was successful
in 483 (35.9%) of them. EGFR was mutated in 59.7% of
patients, and those patients had a 71.2% RR with gefitinib
treatment compared with 47.3% for patients treated with
chemotherapy. In contrast, only 1.1% of patients with no
EGFR mutation responded to gefitinib, whereas 23.5% re-
sponded to chemotherapy. Similarly, PFS was longer in the
gefitinib arm compared with chemotherapy in patients with
EGFR mutations (HR: 0.48, p  0.001). The opposite was
true for patients without mutations (HR: 2.85, p  0.001).
This study led to gefitinib approval as a first-line treatment for
patients with advanced or metastatic NSCLC with underlying
EGFR mutations by the EMEA. A smaller phase III trial
assessing gefitinib versus carboplatin and paclitaxel randomly
assigned 230 chemonaïve patients with EGFR mutations to
receive either gefitinib 250 mg daily or chemotherapy (Table
2).49 The median PFS (10.8 months for gefitinib, 5.4 months
for chemotherapy, p  0.001) and overall RR results (73.7%
for gefitinib, 30.7% for chemotherapy, p  0.001) favored
gefitinib. The median OS numerically, but not statistically,
also favored gefitinib (30.5 months for gefitinib, 23.6 months
for chemotherapy, p  0.31). Finally, Mitsudomi et al.50
demonstrated in a phase III trial, which randomized 177
patients with EGFR-mutant advanced NSCLC to first-line
gefitinib or cisplatin plus docetaxel, an improved RR (62.1%
versus 32.2%, p  0.0001) and longer median PFS (9.2
versus 6.3 months, p 0.0001) in the gefitinib arm (Table 2).
Similar outcomes were replicated with erlotinib, which was
compared with carboplatin and gemcitabine given as first-line
therapy in a randomized phase III trial (OPTIMAL) in 165
patients with advanced/metastatic NSCLC and activating EGFR
mutations (Table 2).51 Patients treated with erlotinib demon-
strated a nearly tripled PFS of 13.1 months in comparison
with a median PFS of 4.6 months with chemotherapy (p 
0.0001). OS data are pending.
Trials testing standard first-line chemotherapy in ad-
vanced/metastatic NSCLC with or without erlotinib or ge-
fitinib failed to show any benefit (Table 2).44–47 They are not
detailed in this review as they have been discussed exten-
sively in the past.9
Prospective and retrospective studies have consistently
shown that both EGFR TKIs and chemotherapy give better
overall outcomes in patients with EGFR mutations compared
with EGFR wild-type.31,48,49,72 EGFR mutations are predic-
tive of a high RR and prolonged PFS in patients treated with
EGFR TKIs, which does not, however, translate into a sig-
nificant benefit in OS. As noted previously, the reason for a
lack of significant impact on OS remains unknown, but
postprogression crossover of control patients to study therapy
could play a role. In addition, it has been demonstrated in a
statistical model that increasing postprotocol survival can
account for diminished OS benefit even if there is no differ-
ence in postprotocol survival between treatment groups.73
EGFR TKIs as Maintenance Therapy
EGFR TKIs are administered orally and have a favor-
able toxicity profile, which supports their possible role as
NSCLC maintenance therapy. Erlotinib was tested as a main-
tenance therapy in an adaptive randomization phase III trial
(SATURN) in 889 unselected patients with NSCLC without
progression after four cycles of platinum doublets (Table 2).52
The trial met its primary end point, demonstrating a 29% risk
reduction in PFS (HR: 0.71, p  0.0001) favoring the
erlotinib maintenance arm. Despite the difference in median
PFS compared with placebo of only 8.4 days (2.9 versus 2.6
months, p  0.0001), it translated into a survival advantage
(12 months for erlotinib versus 11.1 months for placebo, p 
0.0088). EGFR mutation analysis was performed in approx-
imately 40% of patients. Although patients with wild-type













Heymach et al.c65 Phase II, 1st line No CbP  vandetanib 56 32 5.6 10.2
CbP 52 25 5.4 12.6
IGF-1R studies
Karp et al.66 Phase II, 1st line No CbP  figitumumab 98 54 3.6–5 (10 mg/kg
vs. 20 mg/kg)
NR
CbP 53 42 4.3 NR
Jassem et al.67 Phase III, 1st line Nonadenocarcinoma CbP  figitumumab 342 NR NR 8.5
CbP 339 NR NR 10.3
MET studies
Schiller et al.68 Phase II, 2nd line (no
prior EGFR TKI)
No ARQ 197  erlotinib 84 10 3.8 8.5
Placebo  erlotinib 83 7 2.3 6.9
a Time to treatment failure.
b Despite no difference in the median PFS, gefitinib in comparison with chemotherapy reduced the risk of progression by 26% (hazard ratio: 0.74; 95% confidence interval:
0.65–0.85, P  0.001).
c Vandetanib monotherapy arm was discontinued due to lack of efficacy.
RR, response rate; PFS, the median progression-free survival; OS, the median overall survival; CD, cisplatin, docetaxel; CG, cisplatin, gemcitabine; CbP, carboplatin, paclitaxel;
CbG, carboplatin, gemcitabine; CV, cisplatin; vinorelbine; IHC, immunihistochemistry; NR, not reported.
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0.0185), the most striking difference favoring erlotinib (HR:
0.10, p  0.0001) was observed in a small patient subpopu-
lation with EGFR mutations (approximately 10% of the
tested samples). Similarly, a study (ATLAS) testing mainte-
nance therapy with bevacizumab with or without erlotinib
showed prolongation of PFS (4.8 versus 3.7 months, p 
0.0012) but not OS in the erlotinib arm.53
Types of EGFR Mutations
EGFR-activating mutations occur in the region of the
ATP-binding pocket of the tyrosine kinase domain.74 EGFR
mutations target four exons18–20,43 (Table 3).75,76 The most
prevalent mutations associated with sensitivity to EGFR TKIs
are in-frame deletions of exon 19 (44%) and L858R substi-
tutions in exon 21 (41%).77 Nucleotide substitutions in exon
18 and in-frame deletions of exon 20 are less frequent (5%
and 1%, respectively). In the IPASS trial, the subgroup of
66 patients with an exon 19 deletion had a significantly
prolonged PFS after gefitinib treatment compared with car-
boplatin plus paclitaxel, as reflected by a HR of 0.377 (95%
confidence interval: 0.255–0.560).78 RR data showed that
gefitinib produced a response in 84% of patients with exon 19
deletions, and chemotherapy produced responses in 43.2% of
patients. In 64 patients who had an exon 21 L858R mutation,
PFS was increased by gefitinib compared with chemotherapy,
albeit with a less robust HR of 0.553 (95% confidence
interval: 0.352–0.868) and a smaller difference in RR (ge-
fitinib, 60.9% versus chemotherapy, 53.2%). These results
need to be confirmed in other studies. Despite dramatic
responses to EGFR TKIs, most patients eventually develop
disease progression in less than a year.49 A single secondary
mutation, T790M in exon 20, is found in approximately 50%
of patients relapsing after initial response to EGFR
TKIs.22,23,76,79 Much less prevalent is a D761Y secondary
mutation of exon 19 associated with resistance to EGFR TKIs
in less than 1% of patients who initially responded to EGFR
TKIs.80
Irreversible EGFR TKIs
Novel compounds, which irreversibly bind to EGFR
tyrosine kinase and induce less therapeutic resistance in
preclinical experiments, are currently being tested in clinical
studies.81,82 In addition, irreversible EGFR TKI seems to be
active not only in activating mutations but also in mutations
associated with secondary resistance such as T790M. Several
agents including afatinib (formerly BIBW 2992), PF0299804,
and neratinib are in advanced stages of clinical testing.
Afatinib, an irreversible EGFR and HER2 inhibitor, was
compared with placebo in a randomized phase III trial (LUX-
Lung 1) in 585 patients with advanced lung adenocarcinoma
pretreated with one or two prior chemotherapies and at least
12 weeks of prior gefitinib or erlotinib (Table 2).54 There was
no significant difference in OS (primary end point) between
treatment arms (12 months for placebo versus 10.8 months
for afatinib, p  0.74); however, there was a 2.3-month PFS
advantage favoring afatinib (1.1 versus 3.3 months, p 
0.0001). Subanalysis of EGFR mutation status and postpro-
tocol therapies are underway. Afatinib is now being investi-
gated in NSCLC with EGFR, HER2 mutations; EGFR, HER2
amplifications. PF00299804, an irreversible pan-HER inhib-
itor, was compared with erlotinib in a phase II randomized
trial in 188 patients with NSCLC who received one or two
prior chemotherapies but not EGFR TKIs (Table 2).
PF00299804 compared with erlotinib showed an improved
RR (17.1% versus 4.3%, p  0.008) and median PFS (2.9
versus 1.9 months, p  0.017); however, nearly twice as
many patients in the PF00299804 arm were found to have
EGFR mutations than in the erlotinib arm (20.2% versus
11.7%).55
EGFR Monoclonal Antibodies
Cetuximab is a chimeric monoclonal antibody directed
against the extracellular domain of EGFR. Promising results
from randomized phase II trials led to initiation of a study
(FLEX) that compared cisplatin and vinorelbine with or
without cetuximab in 1125 patients with advanced EGFR-
overexpressing NSCLC (Table 2).56,83 Although this trial did
not show any difference in PFS, it met its primary end point,
demonstrating a modest survival gain of 1.2 months for the
cetuximab containing arm (11.3 versus 10.1 months, HR:
0.871, p  0.044). The RR was marginally better in the
cetuximab arm (36% versus 29%). Whether this result is
clinically relevant is debatable; however, patients treated with
cetuximab who developed a skin rash within the first 3 weeks
of treatment achieved an impressive 15-month median sur-
vival versus 8.8 months in patients with no rash.84 Whether
this side effect reflects the higher efficacy of cetuximab, or
whether patients with skin rash have a better prognosis
regardless of a specific treatment regimen, remains to be seen.
Prespecified subanalysis showed that cetuximab provides
benefit irrespective of histology. Biomarker analysis reflect-
ing EGFR copy number on FISH and a GTPase KRAS
(KRAS) mutation showed no significant predictive value for
any of the agents assessed, although the HR favoring cetux-
imab was slightly better in patients with increased EGFR
copy number on FISH.16 A similar trial (BMS099) in 676
nonselected patients with stage IIIB/IV NSCLC did not meet
its primary end point, as the difference in PFS of 0.16 months
favoring the experimental arm did not reach statistical sig-
nificance (Table 2).57 EGFR expression, EGFR copy number,
EGFR mutations, and KRAS mutations did not influence
treatment outcomes.32 The only study suggesting a prognostic
or predictive value associated with EGFR FISH status was a
phase II trial (SWOG 0342) with carboplatin and paclitaxel









Exon 18 G719C, G719S, G719A 5
Exon 19 E746-A750 deletion 44
Exon 20 V756A, T783A 1




Exon 19 D761Y 1
Exon 20 T790M 5
TKIs, tyrosine kinase inhibitors.
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with concurrent or sequential cetuximab.15 Patients with high
EGFR copy numbers had a longer PFS and OS in a retro-
spective analysis. Whether this finding reflects a prognostic
or predictive value of EGFR gene copy status is difficult to
assess, as both treatment arms contained cetuximab.
Biomarker data in studies using cetuximab consistently
showed that mutant KRAS does not predict NSCLC resistance
to cetuximab.16,32 In addition, neither EGFR mutations nor
increased EGFR copy number predicted a favorable response
to cetuximab, suggesting that monoclonal antibodies have
mechanisms of action that differ from EGFR TKIs. Cetux-
imab might interact with other pathways that have not yet
been described and might also alter nonkinase functions of
EGFR, as demonstrated in the preclinical setting.85 Addi-
tional biomarker studies are needed to predict the benefit of
cetuximab in NSCLC.
MET
The MET oncogene encodes a transmembrane receptor
with tyrosine kinase activity.86 MET is involved in complex
prosurvival mechanisms, including downstream activation of
the RAS/RAF/MEK and PI3K/AKT/mTOR pathways (Fig-
ure 1).
MET amplification has been reported in 17% of treat-
ment-naive patients with NSCLC and was associated with a
dismal prognosis and resistance to EGFR TKIs.21–25 Activat-
ing mutations in the tyrosine kinase domain of MET are ob-
served in fewer than 3% of patients, and their biology is not well
understood (Table 1).26–28 Preclinical models have shown that
MET is involved in resistance to angiogenesis inhibitors.87
Antiangiogenic drugs induce HIF-1 expression, which in turn
triggers transcription of multiple genes, including MET.88 This
association provides a rationale for combining MET inhibitors
with EGFR TKIs or antiagiogenic drugs. In addition, MET
amplification is observed in 5 to 20% of patients with
activating EGFR mutations and acquired resistance to
EGFR TKIs.22,23,25
The MET pathway could be inhibited by monoclonal
antibodies against hepatocyte growth factor, monoclonal an-
tibodies against a MET receptor, or by MET TKIs. A recent
phase I trial with a human anti-hepatocyte growth factor
monoclonal antibody AMG102 in combination with the anti-
VEGF monoclonal antibody bevacizumab in patients with
advanced solid tumors demonstrated activity in solid tumors,
including lung cancer.89 An anti-MET receptor monoclonal
antibody, MetMab (PRO143966), is currently being evalu-
ated in a randomized phase II study in combination with
erlotinib. Early results suggest possible benefit in patients
with overexpression of MET.90 ARQ197 is a selective, non-
ATP competitive inhibitor of MET kinase. A phase II ran-
domized trial compared ARQ197 in combination with erlo-
tinib to placebo and erlotinib in chemotherapy pretreated, but
EGFR TKI–naive, patients with advanced NSCLC (Table 2).
The trial did not meet its primary end point as the increase in
median PFS in the experimental arm was not statistically
significant (3.8 versus 2.3 months, p  0.23); however, when
adjusted for prespecified factors such as histology, KRAS, and
EGFR mutations, there was a significant 32% risk reduction
of disease progression in the experimental arm (HR: 0.68,
p  0.05).68 Patients with nonsquamous histology, wild-type
EGFR, and mutated KRAS fared best on the experimental
arm. XL184 is an oral inhibitor of MET, VEGFR, RET, KIT,
and TIE-2. Preliminary data from an ongoing phase Ib/II
study evaluating the safety and efficacy of XL184 in combi-
nation with erlotinib in patients with advanced NSCLC pro-
duced encouraging results in patients with an EGFR T790M
resistance mutation (7/9 patients demonstrated SD) and in
patients with MET amplification (2/2 patients had some tumor
shrinkage).91 Although there is mounting evidence that MET
is an important target in NSCLC, biomarkers predictive for
therapeutic benefit remain to be identified.
VEGFR AND VEGFR
Bevacizumab
In the ECOG 4599 study, bevacizumab, a monoclonal
antibody against VEGF, increased survival (12.3 versus 10.3
months) in patients with nonsquamous NSCLC when added to
standard carboplatin and paclitaxel chemotherapy (Table 2).7
Based on this study, bevacizumab gained Food and Drug
Administration and EMEA approval as first-line therapy
for advanced nonsquamous NSCLC. The AVAiL trial
evaluated the regimen of cisplatin and gemcitabine with
placebo or in combination with one of two doses of
bevacizumab (7.5 or 15 mg/kg every 3 weeks) (Table 2). A
statistically significant but clinically minimal difference of
0.4 to 0.6 months (p  0.03 and p  0.003) in a median
PFS (primary end point) was seen when bevacizumab was
added.58 No dose-effect relationship in the bevacizumab
arms was observed. Nevertheless, the chemotherapy arm
demonstrated a better than expected median PFS of 6.2
months. Updated results revealed no significant difference
in median OS (13.1, 13.6, and 13.4 months, respec-
tively).59 More than 60% of patients treated in this trial
received some postprotocol therapy, which may explain
the lack of survival benefit. Data on postprotocol therapies
from the pivotal ECOG 4599 study are not available,
which precludes drawing definitive conclusions.7 An ad-
ditional conundrum is the lack of validated biomarkers that
can identify which patients are likely to benefit from the
addition of bevacizumab. High blood pressure has been
associated with prolonged PFS and OS when bevacizumab
was added to chemotherapy in a retrospective analysis of
ECOG 4599.92 This needs to be confirmed by other studies
with bevacizumab in NSCLC, including further insight on
the downstream effects of VEGF suppression and hyper-
tension.
VEGF Receptor TKIs
Sunitinib, and sorafenib, TKIs that target multiple ki-
nases, including VEGF receptor (VEGFR), showed promis-
ing results in phase II trials in NSCLC,93,94 although a pivotal
phase III trial (ESCAPE) in 926 patients with advanced
NSCLC demonstrated no advantage when sorafenib was
added to carboplatin and paclitaxel (Table 2).60 Sorafenib was
also tested in a small, randomized discontinuation trial
(ECOG 2501), in which all patients with at least two prior
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chemotherapies received sorafenib for 2 months. Patients
with stable disease were then randomized to sorafenib or
placebo, and the percentage of patients without progression
after 2 months from randomization was a primary end point
(Table 2).61 Despite the trial suffering from a substantial error
in the randomization process, it met its primary end point
demonstrating no progression 2 months after the randomiza-
tion in 47% patients on sorafenib compared with 19% of
patients on placebo.
A randomized phase II trial tested a VEGFR/EGFR/
RET inhibitor, vandetanib, as a monotherapy or in combina-
tion with paclitaxel and carboplatin compared with paclitaxel
and carboplatin in 181 chemonaïve, patients with advanced
NSCLC (Table 2).65 The vandetanib monotherapy arm was
stopped early as it was less effective than chemotherapy. No
survival difference was observed between the two remaining
treatment arms; however, vandetanib added to chemotherapy
delayed progression by 1 week. Vandetanib was also tested as
second-line therapy in combination with docetaxel in a large
phase III trial (ZODIAC), which randomized 1391 patients to
either docetaxel plus vandetanib or docetaxel plus placebo
(Table 2).62 The trial met its primary end point of PFS,
favoring the experimental arm (4 versus 3.2 months, HR:
0.79, p  0.001). The OS did not significantly differ among
treatment arms (10.6 months for docetaxel and vandetanib
versus 10 months with docetaxel and placebo, HR: 0.91, p 
0.196). Two other trials (vandetanib versus erlotinib [ZEST];
and vandetanib with pemetrexed versus placebo with pem-
etrexed [ZEAL]) showed no difference in the median PFS
(Table 2).63,64
Other antiangiogenic treatments, such as VEGFR in-
hibitors (cediranib, motesanib, and pazopanib) and vascula-
ture disrupting agents are being tested in numerous phase III
studies.
EML4-ALK
EML4-ALK fusion is a rare abnormality detected in
approximately 5 to 7% of patients with NSCLC (Table 1),
which seems to be associated with younger age (median: 52
years), male gender, never or light smoking history, adeno-
carcinoma histology, wild-type EGFR, and wild-type
KRAS.29,30,95 Activated ALK, similar to EGFR/HER2, might
constitutively switch on the RAS/RAF/MEK signaling path-
way (Figure 1). Patients with EML4-ALK fusion are resistant
to EGFR TKIs but not to platinum-based chemotherapy.95
Patients with the EML4-ALK fusion demonstrated an
extraordinary response to the MET and ALK inhibitor crizo-
tinib in a phase I/II trial.96 Initially, in the dose-escalation
portion of this trial, a response was seen in a patient with
NSCLC and an underlying EML4-ALK fusion. In the phase II
cohort, 82 patients with NSCLC with EML4-ALK fusion were
assessed. Most of them (59%) had been heavily pretreated
with at least 2 prior regimens. Most patients never smoked
(never smokers 76%, ex-smokers 23%, and current smokers
1%), and all but three had adenocarcinomas. In total, 47 of 82
patients (57%) experienced objective responses and PFS at 6
months was 72%. This trial reiterated the importance of
incorporating prospective molecular profiling into the selec-
tion criteria for early-phase clinical trials examining targeted
therapies. The phase III clinical trial comparing crizotinib
with chemotherapy in a second-line setting is close to com-
pletion.
KRAS
Activating mutations in codons 12 and 13 of the KRAS
oncogene occur in approximately 10 to 30% of lung adeno-
carcinomas.16,31–34 KRAS mutations are usually mutually ex-
clusive to EGFR mutations and occur early in the develop-
ment of smoking-related carcinomas (Table 1).97 Mutant
KRAS is associated with low RRs to EGFR therapies but as
KRAS-mutant lung cancers have similar outcomes on EGFR
TKIs as EGFR wild-type lung cancers it is possible that the
only real impact of KRAS mutation is that its presence implies
an absence of a sensitizing EGFR mutation.14,31,98,99 Al-
though presence of a KRAS mutation did not seem to have an
impact on survival of patients treated with EGFR TKIs or
EGFR monoclonal antibodies in some studies,16,31,32 adding
erlotinib to front-line chemotherapy was associated with a
significant worsening of PFS and OS in patients with KRAS
mutations.72
Because no available drug blocks KRAS directly, stud-
ies are evaluating other potential targets in the RAS/RAF/MEK
pathway that function downstream of KRAS (Figure 1).
Sorafenib, which is a relatively weak RAF inhibitor, showed
efficacy in KRAS-mutant NSCLC in the BATTLE trial, which
was the first completed phase II study with mandatory biopsies
for biomarker analysis and adaptive randomization to four treat-
ment arms: erlotinib, vandetanib, erlotinib plus bexarotene, and
sorafenib.100 At 8 weeks, 79% of patients with KRAS mutations
demonstrated no progression (primary end point), whereas in the
whole study population of 244 patients, the no progression rate
at 8 weeks was 46%. Apart from sorafenib, encouraging pre-
clinical data suggest a potential benefit from MEK inhibitors,
and in a first-in-human phase I clinical trial with GSK1120212,
a MEK inhibitor, 2 (14%) of 14 patients with KRAS-mutant
NSCLC achieved a partial response per Response Evaluation
Criteria in Solid Tumors (RECIST).101,102 These compounds are
currently in the early stages of clinical research.
RECEPTOR TYROSINE PROTEIN KINASE ERBB-2
The HER2 oncogene, a member of the EGFR family,
encodes transmembrane receptors that drive and regulate cell
proliferation.103 The HER2 receptor does not have a known
ligand and is putatively activated by homodimerization with
other HER2 receptors or by heterodimerization, preferentially
with either EGFR or HER3.104 HER2 activates the PI3K/
AKT/mTOR and RAS/RAF/MEK pathways.103
In breast and gastric cancer, HER2 overexpression or
HER2 amplification indicates sensitivity to the anti-HER2
humanized monoclonal antibody trastuzumab.105,106 In
NSCLC, HER2 amplification is found in 2 to 23% of patients;
however, these patients do not seem to benefit from anti-
HER2 monoclonal antibodies (trastuzumab) or HER2 TKIs
(lapatinib).107–110
Interestingly, HER2 mutations in exon 20 of the ty-
rosine kinase domain were found in 3 to 10% of lung
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adenocarcinomas (Table 1).35,36 The most frequent mutation
is YVMA 776-779 ins, which was associated with constitu-
tive activation of HER2 kinase, leading to phosphorylation of
downstream effectors such as AKT and MEK.111 In the same
preclinical experiments, cell lines with mutated HER2 were
also sensitive to the HER2 TKI lapatinib. Similarly, the
pan-HER TKI PF00299804 inhibited cell growth in HER2-
amplified and HER2-mutated NSCLC cell lines resistant to
gefitinib.82 In NSCLC, HER2, EGFR, and KRAS mutations
seem to be mutually exclusive. Nevertheless, a small propor-
tion of patients may have coexisting HER2 and EGFR mu-
tations.36,112 Patients with HER2 mutations are resistant to
EGFR TKIs irrespective of their EGFR mutation status as
progrowth signals are executed through HER2 kinase.111
HER2 receptor provides an attractive target for anticancer
therapy in patients with activating mutations. Several clinical
trials investigating the efficacy of anti-HER2 antibodies (tras-
tuzumab, MGAH22) and HER2 inhibitors (PF00299804, afa-
tinib, neratinib) are currently underway.
PIK3CA
The PI3K/AKT/mTOR pathway is activated in many
cancers, including NSCLC. This signaling pathway plays an
important role in the early stages of lung cancer develop-
ment.113 Molecular aberrations such as amplification or mu-
tations of the p110 subunit, PIK3CA, can lead to the
activation of the pathway. PIK3CA amplification has been
reported in approximately 12 to 17% of patients with NSCLC
and can have a role in EGFR TKI resistance.22,37,38 Mutations
in the helical or kinase domain of PIK3CA were reported in
2 to 13% of patients with NSCLC (Table 1).38–40 Numerous
drugs interfere with this pathway, including PI3K, AKT, and
mTOR inhibitors. Preclinical data and early clinical experi-
ments suggest that coexisting KRAS and PIK3CA mutations
may be associated with resistance to PI3K/AKT/mTOR axis
inhibitors,, but KRAS-mutated NSCLC may respond to a
MEK inhibitor.40,101,114 Importantly, these agents might be
active even in the absence of a PIK3CA mutation owing to
alterations at other levels of the PI3K/AKT/mTOR pathway,
such as PTEN loss, AKT mutations, and other aberrations.115
In addition, activation of the PI3K/AKT/mTOR pathway may
be involved in resistance to EGFR TKIs.116
In the preclinical setting, a dual PI3K and mTOR
inhibitor, BEZ235, demonstrated activity in NSCLC xeno-
grafts with a H1047R PIK3CA mutation.101 Early clinical
data (although not in lung cancer) suggested that treatment,
which includes PI3K/mTOR inhibition in patients with ad-
vanced cancers harboring PIK3CA mutations, might be more
effective than in patients without PIK3CA mutations.5 Mul-
tiple novel pathway inhibitors are currently in clinical devel-
opment. In NSCLC, PI3K inhibitors BKM120, GDC0941
and the AKT inhibitor MK2206 have already transitioned to
phase II studies.
BRAF
BRAF mutations in the G loop (exon 11) or activation
segment (exon 15) of its kinase domain have been reported in
3% of patients with NSCLC.41 BRAF mutations in lung
cancer are early events in lung cancer tumorigenesis, and they
are qualitatively different from V600E BRAF mutations in
malignant melanoma, which may have implications for
BRAF inhibitor efficacy.4 Preclinical data suggested that
BRAF mutations might predict sensitivity of NSCLC cells to
MEK inhibitors (Figure 1).117 This hypothesis is now being
tested in early clinical trials, with several MEK inhibitors
currently in clinical development.
IGF-1R
IGF-1R is a tyrosine kinase receptor and promising
therapeutic target in NSCLC.118 IGF-1R is activated on bind-
ing of the insulin-like growth factor (IGF).119 IGF-1R signal-
ing involves the activation of various intracellular signaling
pathways, including the RAS/RAF/MAP kinase and PI3K/
AKT/mTOR pathways (Figure 1). In operable NSCLC, an
increased copy number of the IGF-1R gene was associated
with a better prognosis.42
A randomized phase II trial demonstrated a better RR
when figitumumab, a monoclonal antibody against IGF-1R,
was added to standard carboplatin and paclitaxel chemother-
apy (54% versus 42%, p  0.001) (Table 2).66 The RRs were
particularly encouraging in tumors with a squamous histol-
ogy, supporting the hypothesis that deregulation of the
IGF-1R pathway may be common in squamous histology
NSCLC.120 Unfortunately, a subsequent phase III trial com-
paring figitumumab plus chemotherapy versus chemotherapy
alone was terminated early for futility (Table 2).67 To put
IGF-1R targeting therapies back on track, we will need to
identify biomarkers predicting therapeutic benefit.
CONCLUSION
The discovery of EGFR mutations revolutionized treat-
ment of NSCLC and triggered the paradigm shift from a
one-size-fits-all to more personalized approaches. Currently,
there are myriad novel therapeutic targets currently being
investigated in laboratory and clinical experiments. An anal-
ysis of the major therapeutic advances in cancer treatment
demonstrated that most breakthroughs, by which drugs pro-
duce very high RRs in a tumor type, have been observed in
uncommon tumors.1 Classic examples, among others, are the
use of KIT kinase inhibitors in KIT mutation-positive GIST
and the use of BCR-ABL inhibitors in chronic myelogenous
leukemia.2,3 These tumor types develop predominantly as a
result of a single molecular aberration; this small repertoire of
underlying single abnormalities may be responsible both for
the rare occurrence of associated tumors and being amenable
to treatment once an appropriate targeted agent is identified.
By contrast, it seems plausible that common tumors, such as
NSCLC, are composed of multiple subsets of disease, each
with its own molecular abnormalities (examples include
EGFR-mutation-positivity, EML4-ALK-positivity, HER2 mu-
tations, and others). Identifying the relevant molecular sub-
types of this heterogeneous disease, and matching patients
with appropriate targeted agents rather than performing large
trials in unselected patients, is crucial if we are to make
headway.121 According to this paradigm, recognizing even
small subsets of disease may be critical. For example, HER2
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mutations are identified in 3 to 10% of patients with NSCLC,
but deregulation of this signal might underlie resistance to
EGFR-directed therapy.35,36,111 It is highly likely that many
patients have several abnormalities driving tumorigenesis and
that single targeted agents will be insufficient for providing
meaningful therapeutic results. Indeed, MET amplification or
mutation is detected in approximately 5 to 20% of patients
with NSCLC and may contribute to resistance to EGFR
therapy.22,23,25 To address this issue, clinical trials that com-
bine EGFR and MET kinase inhibitor therapy have been
developed. In addition, underlying molecular abnormalities
may change over time. It has been observed that patients with
NSCLC with activating EGFR mutations and secondary re-
sistance to EGFR TKIs may lose the mutation underlying
acquired T790M resistance or PIK3CA mutation on discon-
tinuation of EGFR TKIs.22 Therefore, implementing biopsies
in clinical trials, not only before treatment but also at the time
of disease progression, is crucial to future progress. Novel
techniques such as molecular analysis of circulating tumor
DNA might be a solution for patients without disease ame-
nable to biopsy or for tumor DNA collection at multiple time
points.
In conclusion, chemotherapy improves survival in pa-
tients with advanced NSCLC, although its ultimate success
has been limited. New therapeutic combinations involving
targeted therapies and strategies hold promise for improved
treatment outcomes, even in resistant patients. To achieve this
benefit, current classification schemes must be revised to
incorporate molecular features to better address the require-
ments of a targeted therapy approach within the context of
personalized medicine and enable researchers to add prom-
ising new drugs to their therapeutic armamentarium while
sparing patients without relevant molecular aberrations from
unnecessary treatments.
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